Idiopathic Gastroparesis disease: Malacards - Research Articles, Drugs, Genes, Clinical Trials

MCID: IDP093 MIFTS: 28	Idiopathic Gastroparesis Categories: Gastrointestinal diseases, Rare diseases
Genes Related diseases Publications Pathways Drugs Expand all tables

Sources

Aliases & Classifications for Idiopathic Gastroparesis

MalaCards integrated aliases for Idiopathic Gastroparesis:

Name: Idiopathic Gastroparesis ⁵⁸

Classifications:

MalaCards categories:
Global: Rare diseases
Anatomical: Gastrointestinal diseases

See all MalaCards categories (disease lists)

Orphanet: ⁵⁸

Rare gastroenterological diseases

External Ids:

Orphanet ⁵⁸ ORPHA558411

Sources

Summaries for Idiopathic Gastroparesis

MalaCards based summary : Idiopathic Gastroparesis is related to gastroparesis and body mass index quantitative trait locus 11. An important gene associated with Idiopathic Gastroparesis is GHRL (Ghrelin And Obestatin Prepropeptide), and among its related pathways/superpathways are cAMP signaling pathway and Angiogenesis (CST). The drugs Neurotransmitter Agents and Gastrointestinal Agents have been mentioned in the context of this disorder. Related phenotypes are digestive/alimentary and homeostasis/metabolism

Sources

Related Diseases for Idiopathic Gastroparesis

Diseases related to Idiopathic Gastroparesis via text searches within MalaCards or GeneCards Suite gene sharing:

(show all 33)

#	Related Disease	Score	Top Affiliating Genes
1	gastroparesis	29.5	MRC1 HMOX1 GIP GHSR GHRL
2	body mass index quantitative trait locus 11	28.9	HMOX1 GIP GHSR GHRL
3	constipation	10.1
4	alzheimer disease 9	10.0	GHSR GHRL
5	postgastrectomy syndrome	10.0	GIP GHRL
6	growth hormone secreting pituitary adenoma	10.0	GHSR GHRL
7	dumping syndrome	10.0	GIP GHRL
8	ileus	10.0	GHSR GHRL
9	migraine with or without aura 1	9.9
10	cyclic vomiting syndrome	9.9
11	body mass index quantitative trait locus 9	9.9
12	body mass index quantitative trait locus 8	9.9
13	body mass index quantitative trait locus 4	9.9
14	body mass index quantitative trait locus 10	9.9
15	body mass index quantitative trait locus 7	9.9
16	body mass index quantitative trait locus 12	9.9
17	body mass index quantitative trait locus 14	9.9
18	body mass index quantitative trait locus 18	9.9
19	body mass index quantitative trait locus 19	9.9
20	hyperinsulinism	9.9
21	adenocarcinoma	9.9
22	pancreatic adenocarcinoma	9.9
23	neuromuscular disease	9.9
24	median arcuate ligament syndrome	9.9
25	48,xyyy	9.9
26	hypoganglionosis	9.9
27	autonomic dysfunction	9.9
28	acromegaly	9.8	GHSR GHRL
29	functional gastric disease	9.8	GIP GHSR GHRL
30	anorexia nervosa	9.7	GHSR GHRL
31	ectodermal dysplasia 1, hypohidrotic, x-linked	9.6	MRC1 HMOX1
32	ectodermal dysplasia 10b, hypohidrotic/hair/tooth type, autosomal recessive	9.6	MRC1 HMOX1
33	diabetes mellitus	9.3	HMOX1 GIP GHSR GHRL

Graphical network of the top 20 diseases related to Idiopathic Gastroparesis:

Sources

Symptoms & Phenotypes for Idiopathic Gastroparesis

MGI Mouse Phenotypes related to Idiopathic Gastroparesis:

⁴⁶

#	Description	MGI Source Accession	Score	Top Affiliating Genes
1	digestive/alimentary	MP:0005381	9.26	GHRL GHSR GIP PDGFRA
2	homeostasis/metabolism	MP:0005376	9.1	GHRL GHSR GIP HMOX1 MRC1 PDGFRA

Sources

Drugs & Therapeutics for Idiopathic Gastroparesis

Drugs for Idiopathic Gastroparesis (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show all 25)

Name

Status

Phase

Clinical Trials

Cas Number

PubChem Id

Neurotransmitter Agents

Phase 4

Gastrointestinal Agents

Phase 4

Antacids

Phase 4

Anti-Ulcer Agents

Phase 4

Serotonin Receptor Agonists

Phase 4

Serotonin

Investigational, Nutraceutical

Phase 4

50-67-9

5202

Synonyms:

3-(2-Aminoethyl)-1H-indol-5-ol

3-(2-Aminoethyl)indol-5-ol

3-(b-Aminoethyl)-5-hydroxyindole

5 Hydroxytryptamine

5-HT

5-HTA

5-Hydroxy-3-(b-aminoethyl)indole

5-Hydroxyltryptamine

5-Hydroxytriptamine

5-Hydroxytryptamine

5-Hydroxy-tryptamine

Antemovis

DS Substance

Enteramin

Enteramine

Hippophaine

Hydroxytryptamine

Serotonine

sérotonine

thrombocytin

Thrombocytin

thrombotonin

Thrombotonin

Nortriptyline

Approved

Phase 3

72-69-5

4543

Synonyms:

(2)10,11-Dihydro-N-methyl-5H-dibenzo[a,d]cycloheptene-.delta.5.gamma.-propylamine

10,11-Dihydro-5-(3-methylaminopropylidene)-5H-dibenzo(a,d)(1,4)cycloheptene

10,11-Dihydro-N-methyl-5H-dibenzo(a,d)cycloheptene-delta(5,gamma)-propylamine

10,11-Dihydro-N-methyl-5H-dibenzo[a,D]cycloheptene-delta(5,g)-propylamine

10,11-dihydro-N-methyl-5H-dibenzo[a,d]cycloheptene-Delta(5,gamma)-propylamine

10,11-Dihydro-N-methyl-5H-dibenzo[a,D]cycloheptene-Delta(5,gamma)-propylamine

10,11-Dihydro-N-methyl-5H-dibenzo[a,D]cycloheptene-δ(5,g)-propylamine

10,11-Dihydro-N-methyl-5H-dibenzo[a,D]cycloheptene-δ(5,γ)-propylamine

10,11-dihydro-N-methyl-5H-dibenzo[a,d]cycloheptene-Δ5,γ-propylamine

3-(10,11-Dihydro-5H-dibenzo(a,d)cyclohepten-5-ylidene)-N-methylpropylamine

3-(10,11-dihydro-5H-dibenzo[a,d][7]annulen-5-ylidene)-N-methylpropan-1-amine

3-(10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5-ylidene)-N-methyl-1-propanamine

3-(10,11-Dihydro-5H-dibenzo[a,d]cyclohepten-5-ylidene)-N-methyl-1-propanamine

3-(10,11-Dihydro-5H-dibenzo[a,D]cyclohepten-5-ylidene)-N-methyl-1-propanamine

5-(3-(Methylamino)propylidene)dibenzo(a,e)cyclohepta(1,5)diene

5-(3-Methylaminopropylidene)-10,11-dihydro-5H-dibenzo(a,d)cycloheptene

5-(alpha-Methylaminopropylidene)dibenzo(a,d)cyclohepta(1,4)diene

72-69-5

894-71-3

AB00052061

AC1L1IED

Acetexa

Allegron

Altilev

Apo nortriptyline

Apo-nortriptyline

Apotex brand OF nortriptyline hydrochloride

Ateben

Avantyl

Aventyl

AVENTYL HCL

BIDD:PXR0187

BPBio1_000076

BRD-K91263825-003-03-2

BRN 2216786

BSPBio_000068

BSPBio_002111

C07274

CAS-894-71-3

CCRIS 9175

CHEBI:7640

CHEMBL445

CID4543

D08288

DB00540

Demethylamitriptylene

Demethylamitriptyline

Demethylamitryptyline

Desitriptilina

Desitriptyline

Desmethylamitriptylin

Desmethylamitriptyline

Dista brand OF nortriptyline hydrochloride

DivK1c_000151

EINECS 200-788-8

Gen nortriptyline

Gen-nortriptyline

Genpharm brand OF nortriptyline hydrochloride

HMS1920B20

HMS2091J20

HMS500H13

Hydrochloride, nortriptyline

IDI1_000151

KBio1_000151

KBio2_001521

KBio2_004089

KBio2_006657

KBio3_001611

KBioGR_000870

KBioSS_001521

Lilly brand OF nortriptyline hydrochloride

Lopac0_000868

Lopac-N-7261

LS-60753

Lumbeck

Lundbeck brand OF nortriptyline hydrochloride

Mallinckrodt brand OF nortriptyline hydrochloride

MolPort-003-666-245

NCGC00014483

NCGC00014483-02

NCGC00014483-03

NCGC00014483-04

NCGC00014483-11

NCGC00024261-03

NCGC00024261-04

NCGC00024261-05

NCGC00024261-06

nchembio747-comp6

NCI169453

NCI60_001354

NCIOpen2_004361

NCIStruc1_000856

NCIStruc2_000700

NINDS_000151

N-Methyl-3-(10,11-dihydro-5H-dibenzo(a,d)cyclohepten-5-yliden)propylamin

Noramitriptyline

Norfenazin

Noritren

Nortrilen

Nortrilen (TN)

Nortriptilina

Nortriptilina [DCIT]

Nortriptylene hydrochloride

Nortriptylina

nortriptyline

Nortriptyline

Nortriptyline (INN)

Nortriptyline [INN:BAN]

Nortriptyline Hcl

Nortriptyline hydrochloride

Nortriptylinum

Nortriptylinum [INN-Latin]

Nortryptiline

Nortryptyline

Norzepine

Novo nortriptyline

Novo-nortriptyline

Novopharm brand OF nortriptyline hydrochloride

NSC169453

NSC-169453

NSC78248

Nu nortriptyline

Nu pharm brand OF nortriptyline hydrochloride

Nu-nortriptyline

Nu-pharm brand OF nortriptyline hydrochloride

Pamelor

PAMELOR

Pamelor hydrochloride

Paxtibi

PDSP1_001805

PDSP2_001788

Pharmascience brand OF nortriptyline hydrochloride

PMS Nortriptyline

PMS-Nortriptyline

Prestwick0_000254

Prestwick1_000254

Prestwick2_000254

Prestwick3_000254

Psychostyl

QTL1_000063

Ratio nortriptyline

Ratio-nortriptyline

Ratiopharm brand OF nortriptyline hydrochloride

Reig jofre brand OF nortriptyline hydrochloride

Sensaval

Sensival Ventyl

Sesaval

SPBio_001093

SPBio_002287

Spectrum_001041

SPECTRUM1500442

Spectrum2_000997

Spectrum3_000526

Spectrum4_000455

Spectrum5_001377

UNII-BL03SY4LXB

Vividyl

Antidepressive Agents

Phase 3

Antidepressive Agents, Tricyclic

Phase 3

Adrenergic Agents

Phase 3

neurokinin A

Phase 3

Substance P

Phase 3

33507-63-0

44359816

Synonyms:

(2S)-2-{[(2R)-2-({[(2S)-1-[(2S)-6-amino-2-({[(2R)-1-[(2S)-2-amino-5-carbamimidamidopentanoyl]pyrrolidin-2-yl](hydroxy)methylidene}amino)hexanoyl]pyrrolidin-2-yl](hydroxy)methylidene}amino)-1-hydroxy-4-(C-hydroxycarbonimidoyl)butylidene]amino}-N-[(1R)-1-{[(1R)-1-[({[(1R)-1-{[(1S)-1-(C-hydroxycarbonimidoyl)-3-(methylsulfanyl)propyl]-C-hydroxycarbonimidoyl}-3-methylbutyl]-C-hydroxycarbonimidoyl}methyl)-C-hydroxycarbonimidoyl]-2-phenylethyl]-C-hydroxycarbonimidoyl}-2-phenylethyl]pentanediimidate

(2S)-2-{[(2R)-2-({[(2S)-1-[(2S)-6-amino-2-({[(2R)-1-[(2S)-2-amino-5-carbamimidamidopentanoyl]pyrrolidin-2-yl](hydroxy)methylidene}amino)hexanoyl]pyrrolidin-2-yl](hydroxy)methylidene}amino)-1-hydroxy-4-(C-hydroxycarbonimidoyl)butylidene]amino}-N-[(1R)-1-{[(1R)-1-[({[(1R)-1-{[(1S)-1-(C-hydroxycarbonimidoyl)-3-(methylsulphanyl)propyl]-C-hydroxycarbonimidoyl}-3-methylbutyl]-C-hydroxycarbonimidoyl}methyl)-C-hydroxycarbonimidoyl]-2-phenylethyl]-C-hydroxycarbonimidoyl}-2-phenylethyl]pentanediimidate

(2S)-2-{[(2R)-2-({[(2S)-1-[(2S)-6-amino-2-({[(2R)-1-[(2S)-2-amino-5-carbamimidamidopentanoyl]pyrrolidin-2-yl](hydroxy)methylidene}amino)hexanoyl]pyrrolidin-2-yl](hydroxy)methylidene}amino)-1-hydroxy-4-(C-hydroxycarbonimidoyl)butylidene]amino}-N-[(1R)-1-{[(1R)-1-[({[(1R)-1-{[(1S)-1-(C-hydroxycarbonimidoyl)-3-(methylsulphanyl)propyl]-C-hydroxycarbonimidoyl}-3-methylbutyl]-C-hydroxycarbonimidoyl}methyl)-C-hydroxycarbonimidoyl]-2-phenylethyl]-C-hydroxycarbonimidoyl}-2-phenylethyl]pentanediimidic acid

Arg-pro-lys-pro-GLN-GLN-phe-phe-gly-leu-met-NH2

Dopamine

Approved

Phase 2

51-61-6, 62-31-7

681

Synonyms:

(3H)-Dopamine

.alpha.-(3,4-Dihydroxyphenyl)-.beta.-aminoethane

.Beta.-(3,4-Dihydroxyphenyl)ethylamine hydrochloride

1,2-Benzenediol, 4-(2-aminoethyl)- (9CI)

1,2-Benzenediol, 4-(2-aminoethyl)-, hydrochloride

1,2-Benzenediol, 4-(2-aminoethyl)-, labeled with tritium

153C5321-5FEE-4B0B-8925-F388F0EEEBD1

2-(3,4-dihydroxyphenyl)ethylamine

2-(3,4-Dihydroxyphenyl)ethylamine

2-benzenediol

3,4 Dihydroxyphenethylamine

3,4-dihydroxyphenethylamine

3,4-Dihydroxyphenethylamine

3,4-Dihydroxyphenethylamine hydrochloride

3,4-Dihydroxyphenylethylamine

3-Hydroxtyramine

3-Hydroxytyramine

3-Hydroxytyramine Hydrobromide

3-Hydroxytyramine hydrochloride

4-(2-Aminoethyl)-1,

4-(2-aminoethyl)-1,2-benzenediol

4-(2-Aminoethyl)-1,2-benzenediol

4-(2-Aminoethyl)-1,2-bezenediol

4-(2-Aminoethyl)benzene-1,2-diol

4-(2-aminoethyl)catechol

4-(2-Aminoethyl)catechol

4-(2-aminoethyl)pyrocatechol

4-(2-aminoethyl)-pyrocatechol

4-(2-Aminoethyl)pyrocatechol

4-(2-Aminoethyl)-pyrocatechol

4-(2-Aminoethyl)pyrocatechol hydrochloride

50444-17-2

51-61-6

62-31-7 (HYDROCHLORIDE)

a-(3,4-Dihydroxyphenyl)-b-aminoethane

AC1L19S5

AC1Q54AX

AC1Q54AY

AKOS003790978

alpha-(3,4-Dihydroxyphenyl)-beta-aminoethane

ASL 279

BIDD:ER0506

Biomol-NT_000001

BPBio1_001123

BSPBio_001932

C03758

CHEBI:18243

CHEMBL59

CID681

cMAP_000036

cMAP_000065

D07870

DB00988

Deoxyepinephrine

DivK1c_000780

Dopamin

Dopamina

Dopamina [INN-Spanish]

dopamine

Dopamine

Dopamine (INN)

Dopamine (USAN)(*hydrochloride*)

Dopamine [INN:BAN]

Dopamine hydrochloride

Dopaminum

Dopaminum [INN-Latin]

Dopastat

Dophamine

Dynatra

EINECS 200-110-0

HSDB 3068

Hydrochloride, dopamine

Hydroxytyramin

hydroxytyramine

Hydroxytyramine

IDI1_000780

intropin

Intropin

Intropin [*hydrochloride*]

IP 498

KBio1_000780

KBio2_001492

KBio2_002388

KBio2_002484

KBio2_004060

KBio2_004956

KBio2_005052

KBio2_006628

KBio2_007524

KBio2_007620

KBio3_001152

KBio3_002867

KBio3_002962

KBioGR_001129

KBioGR_002388

KBioGR_002484

KBioSS_001492

KBioSS_002393

KBioSS_002491

KW-3-060

L000232

L-DOPAMINE

LDP

Lopac0_000586

Lopac-H-8502

LS-159

Medopa

Medopa (TN)

m-Hydroxytyramine hydrochloride

MolPort-001-641-000

NCGC00015519-01

NCGC00015519-08

NCGC00096050-01

NCGC00096050-02

NCGC00096050-03

NCGC00096050-04

NCGC00096050-05

nchembio.105-comp9

nchembio.107-comp4

nchembio.284-comp1

nchembio.78-comp16

nchembio.89-comp3

nchembio705-8

nchembio801-comp8

NINDS_000780

NSC 173182

NSC169105

NSC173182

Oprea1_088821

Oxytyramine

Pyrocatechol, 4-(2-aminoethyl)- (8CI)

Pyrocatechol, 4-(2-aminoethyl)-, hydrochloride

Revimine

Revivan

SPBio_001205

Spectrum_001012

SPECTRUM1505155

Spectrum2_001023

Spectrum3_000406

Spectrum4_000525

Spectrum5_000945

ST048774

STK301601

UNII-VTD58H1Z2X

UPCMLD0ENAT5885989:001

Metoclopramide

Approved, Investigational

Phase 2

364-62-5

4168

Synonyms:

(metaclopramide)4-Amino-5-chloro-N-(2-diethylamino-ethyl)-2-methoxy-benzamide

(metoclopramide)4-Amino-5-chloro-N-(2-diethylamino-ethyl)-2-methoxy-benzamide

1,5-Dimethyl-2-phenyl-1,2-dihydro-pyrazol-3-one

2576-84-3 (di-hydrochloride)

2-methoxy-4-amino-5-chloro-N,N-(dimethylaminoethyl)benzamide

2-Methoxy-4-amino-5-chloro-N,N-(dimethylaminoethyl)benzamide

2-Methoxy-4-amino-5-chloro-N,N-dimethylaminoethyl)benzamide

2-methoxy-5-chloroprocainamide

2-Methoxy-5-chloroprocainamide

364-62-5

4 Amino-5-chloro-N-(2-(diethylamino)ethyl)-2-methoxybenzamide

4-Amino-5-chloro-2-methoxy-N-(b-diethylaminoethyl)benzamide

4-Amino-5-chloro-2-methoxy-N-(beta-diethylaminoethyl)benzamide

4-amino-5-chloro-2-methoxy-N-(β-diethylaminoethyl)benzamide

4-Amino-5-chloro-2-methoxy-N-(β-diethylaminoethyl)benzamide

4-Amino-5-chloro-N-(2-(diethylamino)ethyl)-2-methoxybenzamide

4-amino-5-chloro-N-(2-(diethylamino)ethyl)-o-anisamide

4-Amino-5-chloro-N-(2-(diethylamino)ethyl)-o-anisamide

4-Amino-5-chloro-N-(2-(diethylamino)ethyl)-O-anisamide

4-amino-5-chloro-N-(2-diethylaminoethyl)-2-methoxybenzamide

4-Amino-5-chloro-N-(2-diethylamino-ethyl)-2-methoxy-benzamide

4-Amino-5-chloro-N-(2-diethylamino-ethyl)-2-methoxy-benzamide (Mcp)

4-Amino-5-chloro-N-(2-diethylamino-ethyl)-2-methoxy-benzamide (metoclopramide)

4-Amino-5-chloro-N-(2-diethylamino-ethyl)-2-methoxy-benzamide(Metoclopramide)

4-amino-5-chloro-N-[2-(diethylamino)ethyl]-2-methoxybenzamide

54143-57-6 (mono-hydrochloride, mono-hydrate)

5-Chloro-2-methoxyprocainamide

7232-21-5 (mono-hydrochloride)

AB00053498

AC1L1HKD

AKOS000280832

Apo-Metoclop

ARONIS24307

Benzamide, 4-amino-5-chloro-N-(2-(diethylamino)ethyl)-2-methoxy- (9CI)

Berk brand OF metoclopramide hydrochloride

Biomol-NT_000082

bmse000779

BPBio1_000217

BPBio1_001100

BRD-K75641298-001-01-5

BRD-K75641298-003-05-2

BRN 1884366

BSPBio_000197

BSPBio_002027

C07868

C14H22ClN3O2

CAS-7232-21-5

Cerucal

CHEBI:107736

CHEMBL86

CID4168

Clopra

CLOPRA-"YELLOW"

Clopra-Yellow

Clopromate

D00726

DB01233

DEL

DEL 1267

Dihydrochloride, metoclopramide

DivK1c_000069

Duraclamid

EINECS 206-662-9

Elieten

Elieten (TN)

Emetid

Emitasol

Emperal

Eucil

Gastrese

Gastrobid

Gastromax

Gastronerton

Gastrosil

Gastrotablinen

Gastrotem

Gastro-Timelets

HMS2089G16

Hydrochloride, metoclopramide

IDI1_000069

Imperan

KBio1_000069

KBio2_002118

KBio2_004686

KBio2_007254

KBio3_001527

KBioGR_001307

KBioSS_002118

L001078

Lopac0_000762

Lopac-M-0763

LS-20038

Maxeran

Maxolon

Meclopran

Metaclopramide

Metaclopromide

Metamide

Methochlopramide

Methoclopramide

Metochlopramide

Metoclol

Metoclopramida

Metoclopramida [INN-Spanish]

metoclopramide

Metoclopramide

Metoclopramide (JP15/INN)

Metoclopramide [INN:BAN:JAN]

Metoclopramide dihydrochloride

Metoclopramide Hcl

Metoclopramide hydrochloride

Metoclopramide Hydrochloride

Metoclopramide Intensol

Metoclopramide monohydrochloride

Metoclopramide monohydrochloride, monohydrate

Metoclopramide Monohydrochloride, Monohydrate

Metoclopramide Omega

Metoclopramidum

Metoclopramidum [INN-Latin]

Metocobil

Metramid

MolPort-000-883-854

Monohydrochloride, metoclopramide

Moriperan

Mygdalon

N-(Diethylaminoethyl)-2-methoxy-4-amino-5-chlorobenzamide

NCGC00015643-01

NCGC00015643-02

NCGC00015643-03

NCGC00015643-08

NCGC00024440-03

NCGC00024440-04

NCI60_003185

Neu-Sensamide

NINDS_000069

Nu-Metoclopramide

o-Anisamide, 4-amino-5-chloro-N-(2-(diethylamino)ethyl)- (8CI)

Octamide

Parmid

Paspertin

Peraprin

Plasil

Plasil (pharmaceutical)

Pms-Metoclopramide

Pramidin

Pramiel

Pramin

Prestwick0_000209

Prestwick1_000209

Prestwick2_000209

Prestwick3_000209

Primperan

Reclomide

Reglan

Reliveran

Rimetin

SPBio_001740

SPBio_002118

Spectrum_001638

Spectrum2_001720

Spectrum3_000504

Spectrum4_000964

Spectrum5_001449

ST024773

Temmler brand OF metoclopramide hydrochloride

Terperan

Terperan (TN)

UNII-L4YEB44I46

Maleic acid

Experimental

Phase 2

110-16-7

444266

Synonyms:

(2Z)-2-Butenedioate

(2Z)-2-Butenedioic acid

(2Z)-But-2-enedioate

(2Z)-But-2-enedioic acid

(2Z)-Butene-2-dioate

(2Z)-Butene-2-dioic acid

(Z)-2-Butenedioate

(Z)-2-Butenedioic acid

(Z)-Butenedioate

(Z)-Butenedioic acid

2-Butenedioate

2-Butenedioic acid

cis-1,2-Ethylenedicarboxylate

cis-1,2-Ethylenedicarboxylic acid

cis-2-Butenedioate

cis-2-Butenedioic acid

cis-But-2-enedioate

cis-But-2-enedioic acid

cis-Butenedioate

cis-Butenedioic acid

H2Male

Hydrogen maleate

Kyselina maleinova

MAE

Maleate

Maleic acid, ammonium salt

Maleic acid, calcium salt

Maleic acid, dipotassium salt

Maleic acid, disodium salt

Maleic acid, iron salt

Maleic acid, monoammonium salt

Maleic acid, monocopper (2+) salt

Maleic acid, monosodium salt

Maleic acid, neodymium salt

Maleic acid, potassium salt

Maleic acid, sodium salt

Maleinic acid

Malenic acid

Malezid CM

Scotchbond multipurpose etchant

Sodium maleate

Toxilate

Toxilic acid

Antiemetics

Phase 2

Dopamine Agents

Phase 2

Dopamine Antagonists

Phase 2

Cola

Phase 2

Pioglitazone

Approved, Investigational

Early Phase 1

111025-46-8

4829

Synonyms:

(+-)-5-((4-(2-(5-ethyl-2-pyridinyl)ethoxy)phenyl)methyl)-2,4-thiazolidinedione

(+-)-5-((4-(2-(5-Ethyl-2-pyridinyl)ethoxy)phenyl)methyl)-2,4-thiazolidinedione

(+/-)-5-[[4-[2-(5-Ethyl-2-pyridinyl)-ethoxy]phenyl]methyl]-2,4-thiazolidinedione

(+/-)-5-[p-[2-(ethyl-2-pyridyl)ethoxy]benzyl]-2,4-thiazolidinedione

(±)-5-((4-(2-(5-ethyl-2-pyridinyl)ethoxy)phenyl)methyl)-2,4-thiazolidinedione

105355-27-9

111025-46-8

198077-89-3

2,4-Thiazolidinedione, 5-[[4-[2-(5-ethyl-2-pyridinyl)ethoxy]phenyl]methyl]- (9CI)

5-((4-(2-(5-Ethyl-2-pyridinyl)ethoxy)phenyl)methyl)-2,4-thiazolidinedione

5-(4-(2-(5-ethyl-2-pyridyl)ethoxy)benzyl)-2,4-thiazolidinedione

5-(4-(2-(5-Ethyl-2-pyridyl)ethoxy)benzyl)-2,4-thiazolidinedione

5-[[4-[2-(5-Ethyl-2-pyridinyl)ethoxy]phenyl]methyl]-2,4-thiazolidinedione

5-[[4-[2-(5-ethylpyridin-2-yl)ethoxy]phenyl]methyl]-1,3-thiazolidine-2,4-dione

5-[[4-[2-(5-ethylpyridin-2-yl)ethoxy]phenyl]methyl]thiazolidine-2,4-dione

5-[[4-[2-[(5-ethyl-2-pyridyl)]ethoxy]phenyl]methyl]thiazolidine- 2,4-dione

5-[4-[2-(5-Ethyl-2-pyridyl)ethoxy]benzyl]thiazolidine-2,4-dione

5-{4-[2-(5-ethylpyridin-2-yl)ethoxy]benzyl}-1,3-thiazolidine-2,4-dione

AB1004597

AC-1021

AC1L1J1Q

Actos

Actos (TN)

Actost

AD 4833

AD-4833

BRD-A48430263-003-02-4

BSPBio_002723

C07675

C19H20N2O3S

CHEBI:8228

CHEMBL595

CID4829

D08378

DB01132

Duetact

Glustin

HMS2089H14

HS-0047

HSDB 7322

I06-0089

KBio2_002103

KBio2_004671

KBio2_007239

KBio3_001943

KBioGR_001619

KBioSS_002103

LS-151327

MolPort-002-508-211

NCGC00163128-01

NCGC00163128-02

nchembio790-comp10

Pioglitazona

Pioglitazona [INN-Spanish]

Pioglitazone

pioglitazone (INN)

Pioglitazone [Ban:Inn]

Pioglitazone [BAN:INN]

Pioglitazone [INN:BAN]

pioglitazone HCl

Pioglitazone HCL

Pioglitazone hydrochloride

Pioglitazone Hydrochloride

Pioglitazonum

Pioglitazonum [INN-Latin]

Poglitazone hydrochloride

SPBio_001897

Spectrum_001623

Spectrum2_001679

Spectrum3_001002

Spectrum4_001130

Spectrum5_001480

Spectrum5_002067

U 72107

U 72107A

U72,107A

U-72107

UNII-X4OV71U42S

Zactos

Olanzapine

Approved, Investigational

132539-06-1

4585 135398745

Synonyms:

132539-06-1

2-methyl-4-(4-methyl-1-piperazinyl)-10 H -thieno[2,3- b ] [1,5]benzodiazepine

2-Methyl-4-(4-methyl-1-piperazinyl)-10H-thieno(2,3-b)(1,5)benzodiazepine

2-methyl-4-(4-methyl-1-piperazinyl)-10H-thieno[2,3-b][1,5]benzodiazepine

2-Methyl-4-(4-methyl-1-piperazinyl)-10H-thieno[2,3-b][1,5]benzodiazepine

2-methyl-4-(4-methylpiperazin-1-yl)-10H-thieno[2,3-b][1,5]benzodiazepine

2-methyl-4-(4-methylpiperazin-1-yl)-5H-thieno[2,3-b][1,5]benzodiazepine

2-methyl-4-(4-methylpiperazin-1-yl)-5H-thieno[3,2-c][1,5]benzodiazepine

AC1L1IHS

AC-665

AKOS000282888

ALKS-7921

BIDD:GT0332

BIDD:PXR0138

Bio-0169

C07322

C076029

C17H20N4S

CHEBI:7735

CHEMBL715

CID4585

CPD000466345

D00454

DB00334

Eli Lilly brand of olanzapine

HMS2051H05

HMS2089M04

HMS2093I04

I06-0784

InChI=1/C17H20N4S/c1-12-11-13-16(21-9-7-20(2)8-10-21)18-14-5-3-4-6-15(14)19-17(13)22-12/h3-6,11,19H,7-10H2,1-2H

InChI=1/C17H20N4S/c1-12-11-13-16(21-9-7-20(2)8-10-21)18-14-5-3-4-6-15(14)19-17(13)22-12/h3-6,11,19H,7-10H2,1-2H3

Jsp001969

KS-1090

L000455

L005958

Lanzac

Lilly brand of olanzapine

LS-152313

LY 170053

LY-170052

LY-170053

Midax

MLS000759457

MLS001165781

MLS001195646

MLS001424057

MolPort-002-885-845

MolPort-003-666-569

MolPort-005-977-341

NCGC00096077-01

NCGC00096077-03

NCGC00096077-04

Olansek

Olanzapin

olanzapina

Olanzapina

olanzapine

Olanzapine

Olanzapine (JAN/USAN/INN)

Olanzapine (OLA)

Olanzapine [USAN:INN]

Olanzapine pamoate

olanzapinum

Olanzapinum

S2493_Selleck

SAM001246652

SMR000466345

SPECTRUM1505024

STK634338

Symbyax

TL8000772

UNII-N7U69T4SZR

Zalasta

Zolafren

Zydis

Zyprexa

Zyprexa (TN)

Zyprexa intramuscular

Zyprexa Intramuscular

Zyprexa Velotab

Zyprexa zydis

Zyprexa Zydis

Hypoglycemic Agents

Early Phase 1

Psychotropic Drugs

Antipsychotic Agents

Serotonin Uptake Inhibitors

Interventional clinical trials:

(show all 15)

#	Name	Status	NCT ID	Phase	Drugs
1	Double-Blind, Randomized, Placebo-Controlled Trial To Assess Efficacy And Safety Of R051619 (Cisapride 10 mg q.i.d.) Versus Placebo For The Improvement Of Symptoms Associated With Exacerbations Of Idiopathic Gastroparesis, After Failure Of Other Treatment Options	Terminated	NCT01281540	Phase 4	Cisapride;Placebo
2	Nortriptyline for Idiopathic Gastroparesis: A Multicenter, Randomized, Double-Masked, Placebo-Controlled Trial (NORIG)	Completed	NCT00765895	Phase 3	Nortriptyline Hydrochloride;Placebo (for nortriptyline)
3	VP-VLY-686-3301: A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase Iii Study To Assess The Efficacy Of Tradipitant In Relieving Symptoms Of Gastroparesis	Recruiting	NCT04028492	Phase 3	Tradipitant;Placebo
4	A 2-Part, Randomized, Double Blind and Open-Label, Placebo and Active-Comparator Controlled Trial to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics for TAK-906 in Subjects With Diabetes Mellitus and Gastroparesis or With Idiopathic Gastroparesis	Completed	NCT03268941	Phase 2	TAK-906 Maleate;Metaclopramide;TAK-906 Maleate Placebo
5	A Multicenter, Double-Blind, Randomized, Placebo-Controlled, Parallel-Group Phase 2 Study to Assess the Efficacy, Safety, and Tolerability of Velusetrag for the Treatment of Diabetic or Idiopathic Gastroparesis	Completed	NCT02267525	Phase 2	Velusetrag;Placebo
6	A Multicenter, Double-Blind, Randomized, Placebo- Controlled, Phase 2 Study to Evaluate Velusetrag Effects on Gastric Emptying in Subjects With Diabetic or Idiopathic Gastroparesis	Completed	NCT01718938	Phase 2	velusetrag dose 1;velusetrag dose 2;velusetrag dose 3;placebo
7	A Dose-Ranging, Randomized, Parallel, Placebo-Controlled Study to Assess the Effect of TAK-954 on Gastrointestinal and Colonic Transit in Patients With Diabetic or Idiopathic Gastroparesis	Completed	NCT03281577	Phase 2	TAK-954;Placebo
8	Effects of Global Osteopathic Manual Treatments on Patients With Idiopathic Gastroparesis	Unknown status	NCT02232334
9	GpR 2: Continuation of the NIDDK Gastroparesis Registry for the Characterization and Clinical Course of Gastroparesis Patients	Completed	NCT01696747
10	Intraluminal Endosonography for Examination of the Structural Changes of the Stomach in Gastroparetic Patients	Completed	NCT01916460
11	Study of the Antro-pyloro-duodenal Motor Dysfunction in Idiopathic Gastroparesis	Completed	NCT01519180
12	Endoscopic Full Thickness Biopsy of the Gastric Wall in Patients With Refractory Idiopathic Gastroparesis: Pilot Study to Detect Neuromuscular and Immune Pathologic Changes	Completed	NCT01650714
13	Pioglitazone for the Treatment of Idiopathic Gastroparesis (PIOGAS Study)	Recruiting	NCT04300127	Early Phase 1	Pioglitazone 30 mg
14	A Pilot Study on the Efficacy and Safety of Olanzapine in Improving Symptoms and Gastric Motility in Gastroparesis	Terminated	NCT01625923		Olanzapine
15	Idiopathic Gastroparesis Registry to Define Severity, Treatment Response, and Prognosis Using a Predominant-Symptom Classification	Terminated	NCT01173484

Search NIH Clinical Center for Idiopathic Gastroparesis

Sources

Genetic Tests for Idiopathic Gastroparesis

Sources

Anatomical Context for Idiopathic Gastroparesis

Sources

Publications for Idiopathic Gastroparesis

Articles related to Idiopathic Gastroparesis:

(show top 50) (show all 154)

#	Title	Authors	PMID	Year
1	Body weight in patients with idiopathic gastroparesis. ⁶¹	Parkman HP...Pasricha PJ	32930463	2021
2	Factors that contribute to the impairment of quality of life in gastroparesis. ⁶¹	Parkman HP...NIDDK/NIH Clinical Gastroparesis Consortium	33493377	2021
3	Efficacy and Safety of Tradipitant in Patients With Diabetic and Idiopathic Gastroparesis in a Randomized, Placebo-Controlled Trial. ⁶¹	Carlin JL...Polymeropoulos MH	32693185	2021
4	Plasma endocannabinoids and cannabimimetic fatty acid derivatives are altered in gastroparesis: A sex- and subtype-dependent observation. ⁶¹	Bashashati M...Sarosiek I	32779297	2021
5	Assessment of pyloric sphincter distensibility and pressure in patients with diabetic gastroparesis. ⁶¹	Desprez C...Gourcerol G	33314491	2020
6	Surgical Treatment for Refractory Gastroparesis: Stimulator, Pyloric Surgery, or Both? ⁶¹	Zoll B...Parkman HP	31512100	2020
7	Clinical efficacy of gastric per-oral endoscopic myotomy (G-POEM) in the treatment of refractory gastroparesis and predictors of outcomes: a systematic review and meta-analysis using surgical pyloroplasty as a comparator group. ⁶¹	Mohan BP...Adler DG	31583465	2020
8	Epidemiology and outcomes of gastroparesis, as documented in general practice records, in the United Kingdom. ⁶¹	Ye Y...Ford AC	32493829	2020
9	Gastric peroral endoscopic pyloromyotomy versus gastric electrical stimulation in the treatment of refractory gastroparesis: a propensity score-matched analysis of long term outcomes. ⁶¹	Shen S...Cai Q	32084672	2020
10	Open-label pilot study: Non-invasive vagal nerve stimulation improves symptoms and gastric emptying in patients with idiopathic gastroparesis. ⁶¹	Gottfried-Blackmore A...Nguyen L	31802596	2020
11	An emerging method to noninvasively measure and identify vagal response markers to enable bioelectronic control of gastroparesis symptoms with gastric electrical stimulation. ⁶¹	Ward MP...Nowak TV	32087238	2020
12	Symptom variability throughout the day in patients with gastroparesis. ⁶¹	Shahsavari D...Parkman HP	31782211	2020
13	The Role of GI Peptides in Functional Dyspepsia and Gastroparesis: A Systematic Review. ⁶¹	Van den Houte K...Tack J	32256403	2020
14	Safety and Feasibility of Per-Oral Pyloromyotomy as Augmentative Therapy after Prior Gastric Electrical Stimulation for Gastroparesis. ⁶¹	Strong AT...El-Hayek K	31610231	2019
15	Proteomics in gastroparesis: unique and overlapping protein signatures in diabetic and idiopathic gastroparesis. ⁶¹	Grover M...Farrugia G	31482734	2019
16	Functional Emesis. ⁶¹	Popa SL...Dumitrascu DL	31517329	2019
17	Prucalopride in Gastroparesis: A Randomized Placebo-Controlled Crossover Study. ⁶¹	Carbone F...Tack J	31295161	2019
18	Abdominal Pain in Patients with Gastroparesis: Associations with Gastroparesis Symptoms, Etiology of Gastroparesis, Gastric Emptying, Somatization, and Quality of Life. ⁶¹	Parkman HP...Pasricha PJ	30852767	2019
19	Transcriptome profiling reveals significant changes in the gastric muscularis externa with obesity that partially overlap those that occur with idiopathic gastroparesis. ⁶¹	Herring BP...Wo JM	31221130	2019
20	Opioid Use and Potency Are Associated With Clinical Features, Quality of Life, and Use of Resources in Patients With Gastroparesis. ⁶¹	Hasler WL...Gastroparesis Clinical Research Consortium	30326297	2019
21	Case Report of gastroparesis healing: 16 years of a chronic syndrome resolved after proximal intercessory prayer. ⁶¹	Romez C...Brown JW	30935546	2019
22	Pathophysiology of idiopathic gastroparesis and implications for therapy. ⁶¹	Bekkelund M...Aabakken L	30638082	2019
23	Epidemiology and Pathophysiology of Gastroparesis. ⁶¹	Moshiree B...Talley NJ	30396519	2019
24	Diabetic Gastroparesis and Nondiabetic Gastroparesis. ⁶¹	Shen S...Cai Q	30396524	2019
25	Bayesian inverse methods for spatiotemporal characterization of gastric electrical activity from cutaneous multi-electrode recordings. ⁶¹	Allegra AB...Coleman TP	31609972	2019
26	Sepiapterin alleviates impaired gastric nNOS function in spontaneous diabetic female rodents through NRF2 mRNA turnover and miRNA biogenesis pathway. ⁶¹	Gangula PR...Sampath C	30285465	2018
27	Wisconsin's Enterra Therapy Experience: A multi-institutional review of gastric electrical stimulation for medically refractory gastroparesis. ⁶¹	Shada A...Gould JC	30072246	2018
28	Pyloric sphincter characteristics using EndoFLIP® in gastroparesis. ⁶¹	Saadi M...Schey R	29709494	2018
29	Efficacy of needleless transcutaneous electroacupuncture in synchronization with breathing for symptomatic idiopathic gastroparesis: A blinded and controlled acute treatment trial. ⁶¹	Song G...McCallum RW	29745434	2018
30	Rome IV Diagnostic Questionnaire Complements Patient Assessment of Gastrointestinal Symptoms for Patients with Gastroparesis Symptoms. ⁶¹	Jehangir A...Parkman HP	29808246	2018
31	Transcriptomic signatures reveal immune dysregulation in human diabetic and idiopathic gastroparesis. ⁶¹	Grover M...NIDDK Gastroparesis Clinical Research Consortium (GpCRC)	30086735	2018
32	Idiopathic gastroparesis is associated with specific transcriptional changes in the gastric muscularis externa. ⁶¹	Herring BP...Wo JM	29052298	2018
33	Therapeutic response to domperidone in gastroparesis: A prospective study using the GCSI-daily diary. ⁶¹	Heckert J...Parkman HP	29110425	2018
34	Per oral endoscopic pyloromyotomy for refractory gastroparesis: initial results from a single institution. ⁶¹	Rodriguez JH...Kroh MD	28567693	2017
35	Gastroparesis: Medical and Therapeutic Advances. ⁶¹	Navas CM...Lacy BE	28721575	2017
36	Gastric neuromuscular histology in patients with refractory gastroparesis: Relationships to etiology, gastric emptying, and response to gastric electric stimulation. ⁶¹	Heckert J...Parkman HP	28374487	2017
37	Diabetic and idiopathic gastroparesis is associated with loss of CD206-positive macrophages in the gastric antrum. ⁶¹	Grover M...NIDDK Gastroparesis Clinical Research Consortium (GpCRC)	28066953	2017
38	Early satiety and postprandial fullness in gastroparesis correlate with gastroparesis severity, gastric emptying, and water load testing. ⁶¹	Parkman HP...NIDDK Gastroparesis Clinical Research Consortium (GpCRC)	27781342	2017
39	Repeat polymorphisms in the Homo sapiens heme oxygenase-1 gene in diabetic and idiopathic gastroparesis. ⁶¹	Gibbons SJ...Farrugia G	29161307	2017
40	Evaluation of prokinetic agents used in the treatment of gastroparesis. ⁶¹	Roe NA...Twilla JD	28265483	2017
41	Gastroparesis as the Sole Presenting Feature of Neuromyelitis Optica. ⁶¹	Salahudeen A...Mistry T	29026864	2017
42	Nausea and vomiting in gastroparesis: similarities and differences in idiopathic and diabetic gastroparesis. ⁶¹	Parkman HP...NIDDK Gastroparesis Clinical Research Consortium (GpCRC)	27350152	2016
43	Gastric Electrical Stimulation for Gastroparesis and Chronic Unexplained Nausea and Vomiting. ⁶¹	Wo JM...Ward MP	27678506	2016
44	Measures of Autonomic Dysfunction in Diabetic and Idiopathic Gastroparesis. ⁶¹	Mohammad MK...Abell TL	27785328	2016
45	Innovative gastric endoscopic muscle biopsy to identify all cell types, including myenteric neurons and interstitial cells of Cajal in patients with idiopathic gastroparesis: a feasibility study (with video). ⁶¹	Rajan E...Farrugia G	27129395	2016
46	Pancreatic Adenocarcinoma Invading the Duodenum and Presenting as Idiopathic Gastroparesis with Nausea and Vomiting. ⁶¹	Cengia BT...Koch KL	27807571	2016
47	Gastric Enterovirus Infection: A Possible Causative Etiology of Gastroparesis. ⁶¹	Barkin JA...Moshiree B	27344315	2016
48	Gastric peroral endoscopic pyloromyotomy (G-POEM) as a salvage therapy for refractory gastroparesis: a case series of different subtypes. ⁶¹	Mekaroonkamol P...Cai Q	27197717	2016
49	[Gastroparesis - causes, diagnosis and treatment]. ⁶¹	Sangnes DA...Dimcevski G	27221182	2016
50	Hydration Strategy for Endurance Running in an Athlete Requiring Home Parenteral Nutrition. ⁶¹	Tillman EM...Nishikawa RA	26150104	2016

Sources

Genes for Idiopathic Gastroparesis

Genes related to Idiopathic Gastroparesis (0 elite genes):

- Elite gene

- Cancer Census gene in COSMIC

#	Symbol	Description	Category	Score	Evidence
1	GHRL	Ghrelin And Obestatin Prepropeptide	Protein Coding	6.93	GeneCards inferred via : Publications (show sections)
2	GHSR	Growth Hormone Secretagogue Receptor	Protein Coding	6.93	GeneCards inferred via : Publications (show sections)
3	GIP	Gastric Inhibitory Polypeptide	Protein Coding	6.93	GeneCards inferred via : Publications (show sections)
4	HMOX1	Heme Oxygenase 1	Protein Coding	6.93	GeneCards inferred via : Publications (show sections)
5	MRC1	Mannose Receptor C-Type 1	Protein Coding	6.93	GeneCards inferred via : Publications (show sections)
6	PDGFRA	Platelet Derived Growth Factor Receptor Alpha	Protein Coding	6.93	GeneCards inferred via : Publications (show sections)

Sources

Variations for Idiopathic Gastroparesis

Sources

Expression for Idiopathic Gastroparesis

Search GEO for disease gene expression data for Idiopathic Gastroparesis.

Sources

Pathways for Idiopathic Gastroparesis

Pathways related to Idiopathic Gastroparesis according to GeneCards Suite gene sharing:

#	Super pathways	Score	Top Affiliating Genes
1	cAMP signaling pathway ³⁶	11.47	GIP GHSR GHRL
2	Angiogenesis (CST) ⁴	11.11	PDGFRA HMOX1
3	Antipsychotics Pathway (Metabolic Side Effects), Pharmacodynamics ⁶⁰	9.92	GHSR GHRL

Sources

GO Terms for Idiopathic Gastroparesis

Cellular components related to Idiopathic Gastroparesis according to GeneCards Suite gene sharing:

#	Name	GO ID	Score	Top Affiliating Genes
1	postsynapse	GO:0098794	9.26	GHSR GHRL
2	secretory granule lumen	GO:0034774	9.16	GIP GHRL
3	cell surface	GO:0009986	9.13	PDGFRA MRC1 GHSR
4	Schaffer collateral - CA1 synapse	GO:0098685	8.62	GHSR GHRL

Biological processes related to Idiopathic Gastroparesis according to GeneCards Suite gene sharing:

(show all 27)

#	Name	GO ID	Score	Top Affiliating Genes
1	negative regulation of inflammatory response	GO:0050728	9.63	GHSR GHRL
2	female pregnancy	GO:0007565	9.63	GIP GHSR
3	response to nutrient levels	GO:0031667	9.62	GIP GHRL
4	negative regulation of tumor necrosis factor production	GO:0032720	9.62	GHSR GHRL
5	negative regulation of interleukin-6 production	GO:0032715	9.61	GHSR GHRL
6	response to estrogen	GO:0043627	9.61	HMOX1 GHRL
7	response to hormone	GO:0009725	9.6	GHSR GHRL
8	hormone-mediated signaling pathway	GO:0009755	9.59	GHSR GHRL
9	negative regulation of interleukin-1 beta production	GO:0032691	9.58	GHSR GHRL
10	positive regulation of insulin secretion	GO:0032024	9.58	GIP GHRL
11	positive regulation of multicellular organism growth	GO:0040018	9.57	GHSR GHRL
12	positive regulation of sprouting angiogenesis	GO:1903672	9.56	GHSR GHRL
13	negative regulation of insulin secretion	GO:0046676	9.55	GHSR GHRL
14	decidualization	GO:0046697	9.54	GHSR GHRL
15	positive regulation of vascular endothelial cell proliferation	GO:1905564	9.52	GHSR GHRL
16	actin polymerization or depolymerization	GO:0008154	9.51	GHSR GHRL
17	regulation of postsynapse organization	GO:0099175	9.49	GHSR GHRL
18	positive regulation of growth	GO:0045927	9.48	GHSR GHRL
19	adult feeding behavior	GO:0008343	9.46	GHSR GHRL
20	postsynaptic modulation of chemical synaptic transmission	GO:0099170	9.43	GHSR GHRL
21	growth hormone secretion	GO:0030252	9.4	GHSR GHRL
22	positive regulation of eating behavior	GO:1904000	9.37	GHSR GHRL
23	regulation of transmission of nerve impulse	GO:0051969	9.32	GHSR GHRL
24	positive regulation of appetite	GO:0032100	9.26	GHSR GHRL
25	regulation of gastric motility	GO:1905333	9.16	GHSR GHRL
26	positive regulation of small intestine smooth muscle contraction	GO:1904349	8.96	GHSR GHRL
27	positive regulation of small intestinal transit	GO:0120058	8.62	GHSR GHRL

Molecular functions related to Idiopathic Gastroparesis according to GeneCards Suite gene sharing:

#	Name	GO ID	Score	Top Affiliating Genes
1	hormone activity	GO:0005179	8.62	GIP GHRL

Sources

Sources for Idiopathic Gastroparesis

¹ BioSystems

² BitterDB

³ CDC

⁴ Cell Signaling Technology

⁵ ClinicalTrials

⁶ ClinVar

⁷ CNVD

⁸ Cochrane Library

⁹ Cosmic

¹⁰ dbSNP

¹¹ DGIdb

¹² Disease Ontology

¹³ diseasecard

¹⁴ DiseaseEnhancer

¹⁵ DISEASES

¹⁶ DrugBank

¹⁷ EFO

¹⁸ ExPASy

¹⁹ FMA

²⁰ GARD

²¹ GeneAnalytics

²² GeneCards

²³ GeneGo (Thomson Reuters)

²⁴ GeneHancer via GeneCards

²⁵ GeneReviews

²⁶ GenomeRNAi

²⁷ GEO DataSets

²⁸ GO

²⁹ GTR

³⁰ HMDB

³¹ HPO

³² ICD10

³³ ICD10 via Orphanet

³⁴ ICD9CM

³⁵ IUPHAR

³⁶ KEGG

³⁷ LifeMap

³⁸ LncRNADisease

³⁹ LOVD

⁴⁰ MalaCards

⁴¹ MedGen

⁴² MedlinePlus

⁴³ MedlinePlus Genetics

⁴⁴ MeSH

⁴⁵ MESH via Orphanet

⁴⁶ MGI

⁴⁷ miR2Disease

⁴⁸ NCBI Bookshelf

⁴⁹ NCI

⁵⁰ NCIt

⁵¹ NDF-RT

⁵² NIH Clinical Center

⁵³ NINDS

⁵⁴ Novoseek

⁵⁵ Novus Biologicals

⁵⁶ OMIM via Orphanet

⁵⁷ OMIM® (Updated 05-Mar-2021)

⁵⁸ Orphanet

⁵⁹ PathCards

⁶⁰ PharmGKB

⁶¹ PubMed

⁶² PubMed Health

⁶³ QIAGEN

⁶⁴ R&D Systems

⁶⁵ Reactome

⁶⁶ Sino Biological

⁶⁷ SNOMED-CT

⁶⁸ SNOMED-CT via HPO

⁶⁹ TGDB

⁷⁰ Tocris

⁷¹ UMLS

⁷² UMLS via Orphanet

⁷³ UniProtKB/Swiss-Prot

⁷⁴ Wikipedia